Common side effects include: Injection site reactions mild pain, redness, swelling, or bruising at the injection site, typically resolving within a few days Headache usually transient and manageable with standard analgesia Nausea or dizziness particularly in the initial treatment phase Skin reactions including itching, mild rash, or acneiform eruptions Temporary urine discolouration red or orange urine is harmless and expected Diarrhoea or flushing usually mild and self-limiting In patients with severe megaloblastic anaemia, low potassium levels (hypokalaemia) may occur during initial intensive treatment, but this is uncommon in routine maintenance therapy
Using the wrong concentration in calculations can result in five-fold or greater dosing errors, making verification essential before every injection
Critically, the limitations of conventional cancer therapies-including efficacy-toxicity tradeoffs and therapeutic resistance-highlight an urgent need for innovative approaches where bioelectromagnetic strategies may offer transformative potential
There is no published human safety dataset for the combination
When used strategically with clinical oversight, peptides can enhance the recovery window, but loading still must be progressive to avoid overstressing healing tissues and reduce the risk of reinjury